Oxford Biomedica Insiders Placed Bullish Bets Worth UK£394.8k

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Oxford Biomedica plc (LON:OXB), that sends out a positive message to the company's shareholders.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Oxford Biomedica Insider Transactions Over The Last Year

The Non-Executive Chair Frederic Doliveux made the biggest insider purchase in the last 12 months. That single transaction was for UK£301k worth of shares at a price of UK£4.50 each. We do like to see buying, but this purchase was made at well below the current price of UK£6.31. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

In the last twelve months insiders purchased 89.13k shares for UK£395k. On the other hand they divested 4.56k shares, for UK£23k. In total, Oxford Biomedica insiders bought more than they sold over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for Oxford Biomedica

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insiders At Oxford Biomedica Have Bought Stock Recently

There was some insider buying at Oxford Biomedica over the last quarter. Member of Innovation & Technology Excellence Board and Independent Director Heather Preston shelled out UK£37k for shares in that time. It's great to see that insiders are only buying, not selling. But in this case the amount purchased means the recent transaction may not be very meaningful on its own.

Insider Ownership Of Oxford Biomedica

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Based on our data, Oxford Biomedica insiders have about 0.4% of the stock, worth approximately UK£3.2m. However, it's possible that insiders might have an indirect interest through a more complex structure. I generally like to see higher levels of ownership.

So What Do The Oxford Biomedica Insider Transactions Indicate?

Insider purchases may have been minimal, in the last three months, but there was no selling at all. The net investment is not enough to encourage us much. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think Oxford Biomedica insiders are doubting the company. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Oxford Biomedica.

But note: Oxford Biomedica may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.